Lunesta Global Regulatory Status: FDA Approval, Label, and Safety Requirements

FDA Approval History and NDA 021476

Eszopiclone was approved by the FDA on December 17, 2004, under New Drug Application 021476, sponsored by Sepracor Inc. (later acquired by Sunovion Pharmaceuticals). The approval was based on a package of randomized, placebo-controlled trials demonstrating efficacy across both sleep onset and sleep maintenance endpoints without the short-term limitation that had appeared on earlier nonbenzodiazepine hypnotic labels.

That absence of a mandated short-term restriction was itself regulatory news. The FDA determined that the clinical data supported chronic use, making Lunesta the first drug in its class where the label did not carry an explicit restriction to short-term (7 to 10 day) therapy.

The Key Trial That Supported Approval

Krystal et al. (Sleep, 2003, N=308) was a 6-month, double-blind, placebo-controlled study in adult outpatients with chronic insomnia. Patients receiving eszopiclone 3 mg reported significantly shorter sleep latency, fewer awakenings, and longer total sleep time compared with placebo across all 6 months, with no evidence of tolerance developing over the study period (1). Subjective sleep quality scores on the PSQI also favored eszopiclone. This durable, 24-week dataset gave the FDA the basis to omit a short-term-only restriction from the original label.

Generic Entry and Subsequent NDA Supplements

Patent protection for the 3 mg dose expired in 2014. The FDA approved the first generic eszopiclone products under the Abbreviated New Drug Application (ANDA) pathway that same year. Multiple sponsors now hold approved ANDAs. Each supplement to NDA 021476, including the 2019 black-box warning, flows automatically into the labeling requirements for all approved generic versions through the FDA's "changes-being-effected" mechanism, meaning every generic label must match the current Reference Listed Drug labeling (2).

DEA Scheduling and Controlled Substance Obligations

Eszopiclone is classified as a Schedule IV controlled substance under the Controlled Substances Act, placed there by the DEA concurrent with FDA approval in 2004. Schedule IV status reflects a finding of accepted medical use combined with a lower potential for abuse relative to Schedule III substances, though abuse and dependence remain real clinical concerns.

Prescriber and Dispensing Requirements

Schedule IV designation imposes specific federal obligations. Prescriptions may be refilled up to five times within 6 months of the original issue date. Federal law does not require a triplicate prescription form for Schedule IV drugs, but individual state regulations may be more restrictive. California, for example, uses the CURES (Controlled Substance Utilization Review and Evaluation System) database, which requires prescribers to check patient history before issuing a Schedule IV prescription.

Abuse Potential Data Cited by the DEA

The DEA scheduling action cited human abuse-potential studies showing that eszopiclone produced subjective effects (euphoria, drug-liking scores) qualitatively similar to those of triazolam, a Schedule IV benzodiazepine, at supratherapeutic doses. Physical dependence after chronic administration at therapeutic doses was documented in animal studies and in some post-market case reports, supporting the Schedule IV rather than Schedule V placement.

Current FDA-Approved Label: Doses, Indications, and Restrictions

The current Lunesta prescribing information (revised following the April 2019 black-box warning update) specifies the indication as treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance in adults. It is not approved for use in patients under 18 years of age (3).

Recommended Dosing by Patient Population

The recommended starting dose is 1 mg immediately before bedtime, with at least 7 to 8 hours remaining before the planned wake time. The dose may be increased to 2 mg or 3 mg if clinically warranted. For elderly or debilitated patients, the maximum recommended dose is 2 mg, reflecting slower clearance in that population. For patients taking strong CYP3A4 inhibitors such as ketoconazole, the starting dose should not exceed 1 mg and the maximum dose is 2 mg.

Women clear eszopiclone more slowly than men. Post-market next-morning driving studies prompted the FDA to issue a Drug Safety Communication in May 2014 recommending that prescribers consider starting women at 1 mg rather than the previously common 2 to 3 mg starting dose. This sex-based dosing guidance was later incorporated into the prescribing information as a formal labeling revision.

Contraindications and Warnings

The label carries one absolute contraindication: known hypersensitivity to eszopiclone or any label component. Hypersensitivity reactions including angioedema of the tongue, glottis, or larynx have been reported and can be fatal.

Additional warnings include:

• CNS depression and next-morning impairment. Patients should not drive or operate heavy machinery the morning after taking eszopiclone until they know how the drug affects them.
• Worsening of depression and suicidal ideation. The label notes that in primarily depressed patients, worsening depression, including suicidal thinking, has been reported.
• Respiratory depression. Eszopiclone should be used with caution in patients with compromised respiratory function.
• Co-administration with CNS depressants. When combined with other CNS depressants, including opioids, the risk of profound sedation, respiratory depression, coma, and death is increased. The FDA's 2016 class-wide boxed warning for opioid and CNS depressant combinations applies here (4).

The 2019 Black-Box Warning: Complex Sleep Behaviors

In April 2019, the FDA required manufacturers of all nonbenzodiazepine hypnotics, including eszopiclone, zaleplon, and zolpidem, to add a black-box warning about complex sleep behaviors. This was the most significant label change since original approval.

What Triggered the Warning

The FDA conducted a comprehensive review of its Adverse Event Reporting System (FAERS) database and identified 66 cases of serious injury or death associated with complex sleep behaviors while patients were taking nonbenzodiazepine hypnotics between 1992 and 2017. Behaviors included sleepwalking, sleep driving, making phone calls, preparing and eating food, and engaging in other activities while not fully awake. Twenty of those 66 cases resulted in death. Critically, some cases occurred at the lowest approved dose and in patients with no prior history of complex sleep behaviors.

Language of the Warning

The FDA's April 2019 Drug Safety Communication stated: "Because the risks of these complex sleep behaviors are so serious, we are requiring these new warnings and a contraindication to be added to the prescribing information and the patient Medication Guide for these medicines." (5)

The contraindication was added for patients who have previously experienced a complex sleep behavior episode while taking any hypnotic. This moved the guidance from a precaution to an absolute contraindication for that subpopulation, a shift the agency made explicitly to reduce recurrent events.

Clinical Implications for Prescribers

Prescribers should document any prior episode of parasomnia or complex sleep behavior before initiating eszopiclone. Patients should be counseled to discontinue the drug and contact their prescriber immediately if they experience any sleep behavior they cannot fully recall. The Medication Guide, which FDA requires to be dispensed with every fill, describes these risks in patient-accessible language.

Post-Market Surveillance and FDA Safety Communications

Post-market safety monitoring for eszopiclone has produced several formal FDA communications beyond the 2019 black-box action.

2013 and 2014 Next-Morning Impairment Actions

In January 2013, the FDA issued a Drug Safety Communication requiring lower recommended doses for zolpidem. In May 2014, the agency extended related next-morning impairment guidance to eszopiclone after reviewing data from controlled driving simulation studies. One key study, McCall et al. (J Clin Psychopharmacol, 2009), documented residual psychomotor impairment in healthy volunteers tested 7.5 hours after eszopiclone 3 mg administration (6). The FDA's communication recommended that the 3 mg dose be avoided when next-day driving is required and that prescribers initiate most patients, particularly women, at 1 mg.

MedWatch and FAERS Reporting

Eszopiclone remains under routine post-market pharmacovigilance through FDA's MedWatch program and the FAERS database. Quarterly FAERS data are publicly accessible and form part of the evidentiary base the FDA uses to assess emerging signals. As of the most recent public FAERS extraction, the most common serious adverse event terms associated with eszopiclone beyond complex sleep behaviors are memory impairment, somnolence, and falls in elderly patients.

International Regulatory Status

The international picture for eszopiclone is substantially more fragmented than the U.S. Story. This fragmentation matters for travelers, telemedicine patients, and clinicians treating internationally mobile patients.

European Union

The European Medicines Agency (EMA) has not granted a centralized marketing authorization for eszopiclone across EU member states. Zopiclone, the racemic parent compound of which eszopiclone is the active S-enantiomer, holds national authorizations in many EU countries (United Kingdom, France, Germany, and others), but eszopiclone itself is not separately approved in most of Europe. Clinicians and patients moving between the U.S. And EU should be aware that a Lunesta prescription carries no legal standing for dispensing in most EU pharmacies.

United Kingdom

Following Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) operates independently of EMA. Zopiclone is approved and widely prescribed in the UK, but eszopiclone does not hold a separate MHRA marketing authorization. Zopiclone is a Class C controlled drug in the UK under the Misuse of Drugs Regulations 2001, a scheduling tier that carries different import and export rules than the U.S. Schedule IV classification.

Canada

Health Canada has not issued a Notice of Compliance (NOC) for eszopiclone. Zopiclone is available in Canada and is classified as a targeted substance. Canadian travelers or patients seeking eszopiclone may find it unavailable through licensed Canadian pharmacies.

Australia and New Zealand

The Therapeutic Goods Administration (TGA) in Australia and Medsafe in New Zealand have not granted marketing authorization for eszopiclone as a distinct compound. Zopiclone holds Schedule 4 (prescription-only) status in Australia; eszopiclone does not appear on the Australian Register of Therapeutic Goods (ARTG).

Japan

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved eszopiclone under the brand name Lunesta in November 2012, making Japan one of the few markets outside the U.S. Where the S-enantiomer has explicit regulatory approval rather than the racemate. The approved dose range in Japan extends to 3 mg, consistent with U.S. Labeling for non-elderly adults.

The table below summarizes regulatory status across key markets as of the article's last-reviewed date.

| Market | Regulatory Body | Eszopiclone Status | Notes | |---|---|---|---| | United States | FDA / DEA | Approved, Schedule IV | NDA 021476; black-box warning since 2019 | | Japan | PMDA | Approved | Approved November 2012 under Lunesta brand | | European Union | EMA | Not centrally approved | Zopiclone (racemate) approved nationally | | United Kingdom | MHRA | Not approved | Zopiclone available as Class C drug | | Canada | Health Canada | Not approved | Zopiclone available as targeted substance | | Australia | TGA | Not approved | Zopiclone on ARTG; eszopiclone absent |

Medication Guide and Patient Communication Requirements

Under 21 CFR 208, FDA classifies eszopiclone as a drug requiring a Medication Guide, meaning pharmacies must dispense the guide with every prescription fill, not just the first. This requirement applies to both brand and generic versions.

The Medication Guide covers five areas: what the drug is, who should not take it, possible serious side effects (leading with complex sleep behaviors and allergic reactions), drug interactions (specifically naming alcohol and opioids), and instructions for taking the drug safely. The guide uses a reading level accessible to patients with a sixth-grade reading comprehension, per FDA readability standards.

Prescribers who dispense samples of Lunesta directly must also provide the Medication Guide with each sample package. Failure to comply is a federal labeling violation.

Comparison with Other Approved Nonbenzodiazepine Hypnotics

Eszopiclone sits within the broader class of nonbenzodiazepine hypnotics, often called "Z-drugs," alongside zolpidem (Ambien, NDA 019908), zaleplon (Sonata, NDA 020803), and the structurally distinct orexin antagonists suvorexant (Belsomra) and lemborexant (Dayvigo). From a regulatory perspective, several differences are worth noting.

Zolpidem immediate-release received FDA approval in 1992, over a decade before eszopiclone. Its label carries a similar black-box warning for complex sleep behaviors (also updated in 2019) and sex-differentiated dosing guidance issued in 2013 (7). Zaleplon has a much shorter half-life of approximately 1 hour compared with eszopiclone's 6 hours, a pharmacokinetic difference that regulators have reflected in different dosing windows and middle-of-the-night dosing provisions.

Suvorexant (Belsomra), approved in 2014 as a Schedule IV orexin receptor antagonist, carries a mechanistically different profile and does not share the GABA-A modulator black-box language, though it has its own warnings for next-morning impairment and abnormal sleep behaviors (8).

A 2017 meta-analysis in BMJ (Huedo-Medina et al., N=13 trials, 4,378 participants) found that Z-drugs as a class produced statistically significant improvements in subjective sleep onset latency and total sleep time compared with placebo, with effect sizes that were modest by conventional clinical thresholds (Cohen d = 0.36 for subjective sleep latency) (9). The regulatory agencies have consistently noted this modest effect size in the context of benefit-risk evaluations.

HealthRX Clinical Perspective on Prescribing Within Label

When initiating eszopiclone, four label-concordant steps reduce medicolegal and safety risk. First, document the insomnia diagnosis and rule out primary sleep apnea, which can worsen with sedative hypnotics. Second, check your state's prescription drug monitoring program (PDMP) database before each new prescription, as required in most states for Schedule IV drugs. Third, start at 1 mg for all patients aged 65 and older and for all women regardless of age, consistent with the current prescribing information. Fourth, ensure the pharmacy dispenses the Medication Guide at every fill, verify this at the first follow-up visit, and document the counseling in the chart.

The FDA's April 2019 contraindication for patients with any prior complex sleep behavior episode is an absolute clinical stop. A prior episode in a patient's medication history requires a different therapeutic approach, not a lower dose of eszopiclone.